Circulating Tumor DNA Clinical Trials

10 recruiting

Circulating Tumor DNA Trials at a Glance

12 actively recruiting trials for circulating tumor dna are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Not Applicable with 4 trials, with the heaviest enrollment activity in Beijing, Poitiers, and Almelo. Lead sponsors running circulating tumor dna studies include Lei Li, GERCOR - Multidisciplinary Oncology Cooperative Group, and Fudan University.

Browse circulating tumor dna trials by phase

Treatments under study

About Circulating Tumor DNA Clinical Trials

Looking for clinical trials for Circulating Tumor DNA? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Circulating Tumor DNA trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Circulating Tumor DNA clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Not Applicable

Danish Vulva Cancer Recurrence Study

SurvivorshipCirculating Tumor DNAVulvar Cancer+6 more
University of Aarhus1,295 enrolled2 locationsNCT06495554
Recruiting

NSCLC Liquid Biopsies and Exhaled VOC

Lung CancerCirculating Tumor DNA
St. Joseph's Healthcare Hamilton210 enrolled1 locationNCT06707519
Recruiting

Feasibility of Circulating Tumour DNA (ctDNA) Analysis Using Automated Capillary Blood Sampling

Colorectal Cancer (Diagnosis)Colorectal Liver Metastasis (CRLM)Circulating Tumor DNA (ctDNA)
Erasmus Medical Center35 enrolled1 locationNCT07310537
Recruiting
Not Applicable

Interest of Circulating Tumor DNA in Digestive and Gynecologic/Breast Cancer

Breast CancerGynecologic CancerCirculating Tumor DNA+2 more
Poitiers University Hospital1,000 enrolled1 locationNCT04530890
Recruiting

ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases

Metastatic Colorectal CancerCirculating Tumor DNA
GERCOR - Multidisciplinary Oncology Cooperative Group232 enrolled16 locationsNCT05787197
Recruiting
Not Applicable

Circulating Tumor DNA Based Adjuvant Chemotherapy in Stage II Colon Cancer Patients: the MEDOCC-CrEATE Trial

Circulating Tumor DNARecurrenceColon Cancer Stage II
UMC Utrecht1,320 enrolled29 locationsNCT06434896
Recruiting
Phase 2

Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer

Circulating Tumor DNALocally Advanced Rectal Carcinoma
Peking Union Medical College Hospital470 enrolled1 locationNCT05601505
Recruiting

Clinical Application of ctDNA Dynamic Monitoring in Neoadjuvant Therapy for HER2-positive Breast Cancer Patients

Breast CancerHER2-positive Breast CancerNeoadjuvant+1 more
The First Affiliated Hospital with Nanjing Medical University50 enrolled1 locationNCT06479460
Recruiting
Phase 3

Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer

High-risk Stage II Colorectal CancerStage III Colorectal CancerCirculating Tumor DNA Methylation
Fudan University340 enrolled1 locationNCT05954078
Recruiting

ctDNA Methylation for Detecting Ovarian Cancer

Circulating Tumor DNAEpithelial Ovarian CancerDNA Methylation+6 more
Lei Li1,400 enrolled1 locationNCT05801276
Recruiting

ctDNA Methylation for Epithelial Ovarian Cancer

Circulating Tumor DNAEpithelial Ovarian CancerDNA Methylation+5 more
Lei Li5,000 enrolled1 locationNCT05801263
Recruiting
Not Applicable

Circulating Tumor DNA Guided Adjuvant Chemotherapy for Colon Cancer

Colon CancerCirculating Tumor DNA
Peking University Cancer Hospital & Institute2,684 enrolled1 locationNCT05529615